Novo Nordisk stock kpis
Want to see NVO full AI Analyst Report?
Revenue by Segment
In Q3 2026, Novo Nordisk reported revenue by segment of kr47.55B (Diabetes), kr26.15B (Obesity) and kr5.50B (Rare Disease).
Details revenue from various business segments, providing insight into Novo Nordisk's diverse income streams and strategic focus areas.
Novo’s revenue mix is visibly shifting: Diabetes remains the largest, but growth is now more muted and lumpy, while the obesity franchise has surged since 2022 to become the company’s primary growth engine. Rare disease sales are steady but too small to move the needle. That trade-off boosts upside from blockbuster obesity drugs but raises concentration risk—future results will hinge on continued market adoption, pricing dynamics and competitive/regulatory pressure in the GLP‑1 space.
NVO Revenue by Segment
| Period | Diabetes | Obesity | Rare Disease |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | kr47.55B | kr26.15B | kr5.50B |
| Q2 2026Jun 30, 2026 | kr50.43B | kr23.15B | kr4.91B |
| Q1 2026Mar 31, 2026 | kr44.94B | kr20.91B | kr4.21B |
| Q4 2025Dec 31, 2025 | kr51.35B | kr22.45B | kr5.35B |
| Q3 2025Sep 30, 2025 | kr49.15B | kr21.11B | kr4.72B |
| Q2 2025Jun 30, 2025 | kr51.57B | kr20.37B | kr4.92B |
| Q1 2025Mar 31, 2025 | kr55.04B | kr18.42B | kr4.62B |
| Q4 2024Dec 31, 2024 | kr58.57B | kr21.41B | kr5.71B |
| Q3 2024Sep 30, 2024 | kr47.94B | kr18.80B | kr4.57B |
| Q2 2024Jun 30, 2024 | kr50.18B | kr13.90B | kr3.98B |
| Q1 2024Mar 31, 2024 | kr49.93B | kr11.04B | kr4.38B |
| Q4 2023Dec 31, 2023 | kr50.06B | kr11.23B | kr4.57B |
| Q3 2023Sep 30, 2023 | kr42.57B | kr12.26B | kr3.90B |
| Q2 2023Jun 30, 2023 | kr39.88B | kr10.31B | kr4.11B |
| Q1 2023Mar 31, 2023 | kr40.95B | kr7.84B | kr4.58B |
| Q4 2022Dec 31, 2022 | kr37.75B | kr5.49B | kr4.85B |
| Q3 2022Sep 30, 2022 | kr36.13B | kr4.33B | kr5.11B |
| Q2 2022Jun 30, 2022 | kr32.40B | kr3.64B | kr5.22B |
| Q1 2022Mar 31, 2022 | kr33.27B | kr3.40B | kr5.36B |
| Q4 2021Dec 31, 2021 | kr31.16B | kr2.46B | kr4.71B |
| Q3 2021Sep 30, 2021 | kr28.72B | kr2.40B | kr4.51B |
| Q2 2021Jun 30, 2021 | kr26.04B | kr1.99B | kr5.01B |
| Q1 2021Mar 31, 2021 | kr27.28B | kr1.55B | kr4.98B |
| Q4 2020Dec 31, 2020 | kr23.61B | kr1.21B | kr4.47B |
| Q3 2020Sep 30, 2020 | kr23.77B | kr1.46B | kr4.80B |
| Q2 2020Jun 30, 2020 | kr24.01B | kr1.44B | kr4.82B |
| Q1 2020Mar 31, 2020 | kr25.77B | kr1.56B | kr5.09B |
| Q4 2019Dec 31, 2019 | kr27.01B | kr1.58B | kr5.28B |
| Q3 2019Sep 30, 2019 | kr24.01B | kr1.31B | kr4.69B |
| Q2 2019Jun 30, 2019 | kr25.01B | kr1.34B | kr4.58B |
| Q1 2019Mar 31, 2019 | kr26.38B | kr1.39B | kr4.37B |

